Presentation
Empirical Assessment of Privacy Risks in Data
Blog
COVID-19: Recommended readings and resources from Aetion scientists
Over the past few weeks, we’ve been adjusting to the many changes and uncertainties ...
Blog
Making the business case for RWE: Julie Schiffman’s advice for biopharma on leveraging data to drive impact
How can teams within biopharma ensure their real-world evidence (RWE) studies make the ...
Blog
Psychiatrist and health care CEO Dr. Gary Gottlieb: Treating the patient as a whole person
With his previous professional experience ranging from CEO of Massachusetts-based ...
Blog
Aetion, Dr. Scott Gottlieb, biopharma leaders’ discussions at JPM 2020: It’s time to “knock on an open door” to further RWE standards and acceptance
This January, in the whirlwind week of the 36th Annual J.P. Morgan Healthcare Conference ...
Blog
How to amplify RWE clarity and reproducibility with data visualizations: Q&A with Dr. Shirley Wang of the REPEAT initiative
While analyses of non-randomized health care databases—insurance claims, electronic ...
Blog
Artificial Intelligence in Health Care - GAO Report
Benefits and Challenges of Machine Learning in Drug Development The adoption of ...
Presentation
Ten Things I Have Learned About Health Data Monetization
Khaled El Emam, SVP & GM, Replica Analytics
Blog
Why diverse data teams lead to bigger wins, and other perspectives from retail tech: A Q&A with Stitch Fix CTO, Cathy Polinsky
Cathy Polinsky’s deep love of programming, problem-solving, and perfecting client ...
Blog
How emerging technologies will ensure increasing availability of RWD
The potential of real-world data (RWD) to transform clinical trials is drawing attention ...
Blog
Contextual considerations in RWE generation and use
There’s a lot of buzz around the potential impact of real-world evidence (RWE) in health ...
Blog
The shift from health technology assessment to management: What is RWE’s role?
As innovation in health care advances—and the associated costs escalate—payers are ...
Presentation
Ten Things I Have Learned About De-identification
Blog
RWE use by HTAs: How has it evolved, and where is it headed next? Q&A with Dr. Jens Grueger
Health technology assessment (HTA) agencies are increasingly turning to real-world ...
Tutorial
Tutorials | What is Synthetic Data ?
A general introduction and overview of synthetic data and its uses.
Tutorial
Tutorials | Managing Identity Disclosure
An overview of the key privacy risks that data synthesis is meant to manage.
Tutorial
Tutorials | When to Synthesize
Making a case for using and getting value from synthetic data.
Blog
RWE and the value equation: U.S. health care purchaser perspectives on payment model evolution and the role of RWE
Much discussion surrounds rising drug prices—and the numerous parties affected. ...
Tutorial
Tutorials | Privacy Law & Synthetic Data
International trends in privacy law relating to synthetic data.*
Tutorial
Tutorials | How Good is Synthetic Data ?
Defining and assessing the “goodness” of synthetic data
Tutorial
Tutorials | Enabling AI
Using data synthesis to enable Artificial Intelligence.
Blog
Let’s talk about value: How biopharma can maximize utility of RWE in value discussions
With the drug pricing pressures mounting on a global scale, there is a clear and imminent ...
Blog
Ask our experts: Working with real world data sets: What types of questions can your data answer?
The promise of real-world evidence (RWE) comes with a steep learning curve. As regulators ...
Blog
Managing the Risks from AI Algorithms
In the webinar organized by Replica Analytics in November 2019 entitled "Managing the ...